(6-9%Y.) control vs 8/106 (7.5%) treated, a non-significant 12% increase (SD 56, 2p 
125 Sscanning or venography), pulmonary embolism, death from all causes, haemorrhagic transformation of cerebral infarction, level of disability in survivors. In patients with acute ischaemic stroke, allocation to heparin was associated with a highly significant 81% (SD 8 ( and probably also pulmonary embolism) and possibly a one fifth reduction in mortality (equivalent to the avoidance of 20-40 early deaths per thousand patients treated). However, the data were wholly inadequate on safety, particularly on the risk of haemorrhagic transformation of the infarct and on the hazards of heparin therapy in patients with known intracerebral haemorrhage.
The trials of oral anticoagulants (15 deaths among 57 patients) and antiplatelet therapy (two deaths among 103 patients)
were too small to be informative. Much larger randomised trials-comparing aspirin, heparin and the combination of both drugs against control-in patients with acute ischaemic stroke are justified (and several are now planned or underway).
(J Neurol Neurosurg Psychiatry 1993;56: [17] [18] [19] [20] [21] [22] [23] [24] [25] Each year, there are about 1-5 million new strokes per year in the USA and in the European Community. [1] [2] [3] Eighty five per cent of strokes are ischaemic,3 so over the next decade, there will be some 12-8 million patients with acute ischaemic stroke, for whom antithrombotic treatment might be considered. Of these patients, about 15 million will be dead within two weeks of their stroke. Many will survive, but be dependent on (9) 87% (16) 85% (8) 79% (8) 
pooled data from trials of acute treatment with trials of long-term secondary prevention.42 In the present overview in patients with acute, presumed ischaemic stroke, allocation to heparin therapy was associated with a highly significant 81% reduction in the odds of DVT. Proportional reductions in DVT were similar with standard heparin, LMW heparin, fixed low-dose regimes and adjusted full-dose regimes. Reductions were similar in patients with acute CT confirmed ischaemic stroke, with presumed ischaemic stroke and with acute haemorrhagic stroke. Heparin had similar effects on DVT in stroke patients as in patients experiencing different types of surgery'3 and in patients with acute MI.37 In the present overview, the reductions in the absolute risk of DVT were substantial: heparin therapy ' reduced DVT from 57% among controls to 15% among treated patients. There were insufficient events in the present overview to deter-| mine whether the reduction in DVT would et lead to a reduction in pulmonary embolism (PE) in stroke patients. However, the observed 58% reduction in PE with heparin prophylaxis for stroke patients was similar to the results of heparin prophylaxis in surgical patients (47% reduction in PE)"3 and in patients with acute
En MI (54% reduction in PE). 37 
